"10.1371_journal.pmed.0030177","plos medicine","2006-05-16T00:00:00Z","Nancy J Sullivan; Thomas W Geisbert; Joan B Geisbert; Devon J Shedlock; Ling Xu; Laurie Lamoreaux; Jerome H H V Custers; Paul M Popernack; Zhi-Yong Yang; Maria G Pau; Mario Roederer; Richard A Koup; Jaap Goudsmit; Peter B Jahrling; Gary J Nabel","Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America; United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, United States of America; Crucell Holland B.V., Leiden, Netherlands; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America","NJS, TWG, JBG, DJS, LL, and PMP contributed to animal experiments. NJS, DJS, LL, and PMP contributed to immune analyses. NJS, TWG, MGP, MR, RAK, JG, PBJ, and GJN contributed to experimental design. NJS, TWG, MGP, MR, RAK, JG, PBJ, and GJN contributed to data evaluation. NJS, TWG, MGP, PBJ and GJN participated in writing of the paper. LX, JHHVC, ZYY, and MGP contributed to vector construction and production.","GJN: Intellectual property on gene-based vaccines for Ebola. NJS: Intellectual property on gene-based vaccines for Ebola. ZYY: Intellectual property on gene-based vaccines for Ebola. The company Crucell is developing an Ebola vaccine.","2006","05","Nancy J Sullivan","NJS",15,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
